Lensar - W/I | 10-Q: FY2025 Q1 Revenue Beats Estimate at USD 14.16 M

Revenue: As of FY2025 Q1, the actual value is USD 14.16 M, beating the estimate of USD 13.4 M.

EPS: As of FY2025 Q1, the actual value is USD -2.32, missing the estimate of USD -0.155.

EBIT: As of FY2025 Q1, the actual value is USD -26.43 M.

Segment Revenue

• Product Revenue: $10,918 thousand for the three months ended March 31, 2025, compared to $7,433 thousand for the same period in 2024, representing a 47% increase.
• Lease Revenue: $1,884 thousand for the three months ended March 31, 2025, compared to $1,947 thousand for the same period in 2024, representing a 3% decrease.
• Service Revenue: $1,357 thousand for the three months ended March 31, 2025, compared to $1,208 thousand for the same period in 2024, representing a 12% increase.

Operational Metrics

• Net Loss: - $27,345 thousand for the three months ended March 31, 2025, compared to - $2,157 thousand for the same period in 2024.
• Operating Loss: - $5,790 thousand for the three months ended March 31, 2025, compared to - $2,850 thousand for the same period in 2024.
• Total Operating Expenses: $12,915 thousand for the three months ended March 31, 2025, compared to $8,514 thousand for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $6,938 thousand for the three months ended March 31, 2025, compared to - $5,307 thousand for the same period in 2024.
• Net Cash Provided by Investing Activities: $531 thousand for the three months ended March 31, 2025, compared to - $1,226 thousand for the same period in 2024.
• Net Cash Provided by Financing Activities: $9,691 thousand for the three months ended March 31, 2025, compared to - $130 thousand for the same period in 2024.

Unique Metrics

• Change in Fair Value of Warrant Liabilities: - $21,714 thousand for the three months ended March 31, 2025, compared to $495 thousand for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company is focused on continuous innovation and has launched its proprietary next-generation ALLY System, which is designed to transform premium cataract surgery by utilizing advanced robotic technologies.
• Proposed Acquisition by Alcon: LENSAR, Inc. entered into a Merger Agreement with Alcon Research, LLC, which is expected to close in mid-to-late 2025, subject to customary closing conditions, including approval by stockholders and regulatory approvals.